Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580302 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL11449382 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL18529411 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL237109 | 0.83 | — | — | |
| SCHEMBL18316485 | 0.83 | — | — | |
| SCHEMBL23531398 | 0.83 | — | — | |
| SCHEMBL18529410 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL20479158 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL21530869 | 0.83 | — | — | |
| SCHEMBL311380 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10092485-B2 | Benefit agent delivery particle | ENCAPSYS, LLC | 2018-10-09 | — | — | US | claimed |
| EP-3234094-A1 | IONIC LIQUID SYSTEMS | The Procter and Gamble Company (US) | 2017-10-25 | — | — | EP | claimed |
| EP-2160176-B1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016100123-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2016-06-23 | — | — | WO | claimed |
| US-RE45538-E1 | Benefit agent containing delivery particle | THE PROCTER & GAMBLE COMPANY (US) | 2015-06-02 | — | — | US | claimed |
| EP-2418267-B1 | Benefit agent containing delivery particle | PROCTER & GAMBLE (US) | 2013-07-10 | — | — | EP | claimed |
| EP-2557148-A1 | Benefit agent containing delivery particle | APPLETON PAPERS INC. (US) | 2013-02-13 | — | — | EP | claimed |
| EP-2094828-B1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | APPLETON PAPER INC (US) | 2013-01-02 | — | — | EP | claimed |
| EP-2431457-A1 | Benefit agent containing delivery particle | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2418267-A1 | Benefit agent containing delivery particle | The Procter & Gamble Company (US) | 2012-02-15 | — | — | EP | claimed |
| US-7968510-B2 | Benefit agent containing delivery particle | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-28 | — | — | US | claimed |
| EP-3052551-B1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3234094-A1 | IONIC LIQUID SYSTEMS | The Procter and Gamble Company (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170065996-A1 | Dispensers For Microcapsules | PROCTER & GAMBLE (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160376522-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2016-12-29 | — | — | US | disclosed |
| WO-2016100123-A1 | IONIC LIQUID SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015051139-A1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | APPVION, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2845896-A1 | Benefit agent containing delivery particle | The Procter and Gamble Company (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2431457-A1 | Benefit agent containing delivery particle | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2418267-A1 | Benefit agent containing delivery particle | The Procter & Gamble Company (US) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376522-A1 | IONIC LIQUID SYSTEMS | CUTA, POLR1C, PIK3C3 | ALDH1A1 2657/4885CYP3A4 1777/4885ALOX15 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.